Indaptus Therapeutics Inc
Research Indaptus Therapeutics Inc (INDP) on Bullrun: market cap USD 325.11M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerINDP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 325.11M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 1.79M
- Free cash flow-USD 1.93M
Valuation Snapshot
latest market cap is USD 325.11M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 20.85M | -USD 14.82M | n/a | -21.58 | USD 8.51M | USD 0 | USD 3.15M |
| FY2024 | USD 0 | -USD 15.02M | -USD 12.32M | n/a | -44.96 | USD 5.79M | USD 84.16K | USD 3.94M |
| FY2023 | USD 0 | -USD 15.42M | -USD 13.41M | n/a | -1.83 | USD 13.36M | USD 175.05K | USD 12.08M |
| FY2022 | USD 0 | -USD 14.32M | -USD 13.08M | n/a | -1.73 | USD 9.63M | USD 80.49K | USD 24.63M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 325.11M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 6.31M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 10.12M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 14.78M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 12.18M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 47.07M | n/a | n/a | n/a |
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Indaptus Therapeutics Inc's market cap?
Indaptus Therapeutics Inc's market capitalization is USD 325.11M.
What does Indaptus Therapeutics Inc do?
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc.